Jul. 29 at 4:29 PM
The B2i Digital team is pleased to welcome Xtant Medical Holdings, Inc. (NYSE American:
$XTNT) as the newest B2i Digital Featured Company. A full investor profile will be posted soon at https://b2idigital.com/featured-companies.
Xtant Medical is a global medical technology company that develops, manufactures, and markets biologics and spinal implant systems for orthopedic and neurosurgical specialists. Its vertically integrated platform is distinguished by its inclusion of all five major orthobiologic categories, in addition to amniotic membranes for advanced wound care.
Investment and financial highlights include a “best-in-class” portfolio of orthobiologics that fully covers all five product lines, including demineralized bone graft, cellular allograft, allograft, synthetic bone graft, and marrow-derived growth factor. The company has established exceptional market access through 450 integrated delivery network (IDN) contracts and a network of more than 670 independent distributors.
Xtant Medical operates within a significant addressable market, consisting of a
$10.1 billion worldwide spine market and a
$2.5 billion U.S. orthobiologics market. A robust R&D pipeline is in place to develop next-generation biologics, with several products launched in 2024 and additional launches scheduled this year and next.
See full press release: https://www.newmediawire.com/news/xtant-medical-partners-with-b2i-digital-to-educate-investors-on-its-orthobiologics-innovation-and-market-opportunity-7081558
The company is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, whose collective experience spans medical-device commercialization, corporate finance, and orthobiologologic innovation. For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSciences Advisors,
[email protected].
Disclosure: The management of B2i Digital may purchase shares of unrestricted XTNT stock in the open market, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the purchase or sale of XTNT or any security, nor does it offer any investment opinion. Conduct your own research and consult professional advisers before making investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/